These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 24613899)

  • 1. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
    Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
    Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
    Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
    Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy.
    Sun Y; Wu H; Chen G; Huang X; Shan Y; Shi H; Zhang Q; Zheng Y
    Mol Med Rep; 2018 Jan; 17(1):300-306. PubMed ID: 29115604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy.
    Xu X; Sun Q; Yu X; Zhao L
    Virus Res; 2017 Apr; 233():35-41. PubMed ID: 28286036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
    Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
    Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
    Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
    Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation.
    Bahrambeigi V; Ahmadi N; Salehi R; Javanmard SH
    Immunol Invest; 2015; 44(3):216-36. PubMed ID: 25565576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.
    Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W
    J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
    Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
    Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V; Haas C; Bonifer R; Ertel C
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy.
    Zhao H; Janke M; Fournier P; Schirrmacher V
    Virus Res; 2008 Sep; 136(1-2):75-80. PubMed ID: 18538434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.
    Xu X; Sun Q; Mei Y; Liu Y; Zhao L
    Cancer Sci; 2018 Feb; 109(2):279-288. PubMed ID: 29224228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy.
    Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D
    Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
    Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
    Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.